What patient outcomes were observed in the UBT251 Phase 1b trial?

Question

Accepted Answer

Observed Patient Outcomes in UBT251 Phase 1b Trial

In the Phase 1b trial of UBT251, participants in the highest dose group experienced a significant average weight reduction, while the placebo group saw a slight weight increase. The safety profile of UBT251 was found to be consistent with existing incretin-based therapies, with the majority of adverse events being mild to moderate gastrointestinal issues.
Significant Weight Reduction in Highest Dose Group

Individuals who completed the trial in the highest dosage group of UBT251 demonstrated an average weight decrease of 15.1% from their baseline measurements. This contrasts with the control group, where participants receiving a placebo experienced an average weight gain of 1.5% over the same trial period.
Consistent Safety Profile with Incretin Therapies

The safety and tolerability assessment of UBT251 indicated a profile that aligns with established incretin-based therapeutic agents. This suggests that the observed side effects are generally predictable within this class of drugs.
Predominance of Mild to Moderate Gastrointestinal Events

The most frequently reported adverse events during the trial were gastrointestinal in nature. Crucially, the overwhelming majority of these events were classified as mild to moderate in severity, indicating a generally well-tolerated experience for most participants.

Reading history

Hide →

This history is cleared when the page is closed.

What patient outcomes were observed in the UBT251 Phase 1b trial?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

1

0

0

Share with friends